SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii

Acinetobacter baumannii is responsible for 10% of all nosocomial infections and has >50% mortality rates when causing ventilator-associated pneumonia. In this proof-of-concept study, we evaluated SPR741, an antibiotic adjuvant that permeabilizes the Gram-negative membrane, in combination with rif...

Descripción completa

Detalles Bibliográficos
Autores principales: Zurawski, Daniel V., Reinhart, Alexandria A., Alamneh, Yonas A., Pucci, Michael J., Si, Yuanzheng, Abu-Taleb, Rania, Shearer, Jonathan P., Demons, Samandra T., Tyner, Stuart D., Lister, Troy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2017
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700309/
https://www.ncbi.nlm.nih.gov/pubmed/28947471
http://dx.doi.org/10.1128/AAC.01239-17
Descripción
Sumario:Acinetobacter baumannii is responsible for 10% of all nosocomial infections and has >50% mortality rates when causing ventilator-associated pneumonia. In this proof-of-concept study, we evaluated SPR741, an antibiotic adjuvant that permeabilizes the Gram-negative membrane, in combination with rifampin against AB5075, an extensively drug-resistant (XDR) A. baumannii strain. In standard in vitro assays and in a murine pulmonary model, we found that this drug combination can significantly reduce bacterial burden and promote animal survival despite an aggressive infection.

Ejemplares similares